DexCom, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DXCM research report →
About the company
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
- CEO
- Jacob Steven Leach
- IPO
- 2005
- Employees
- 10,200
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $27.49B
- P/E
- 29.69
- P/S
- 5.71
- P/B
- 9.28
- EV/EBITDA
- 18.81
- Div Yield
- 0.00%
- Gross Margin
- 61.84%
- Op Margin
- 21.45%
- Net Margin
- 19.31%
- ROE
- 33.83%
- ROIC
- 18.03%
- Revenue
- $4.66B · 15.60%
- Net Income
- $836.30M · 45.14%
- EPS
- $2.14 · 46.58%
- Op Income
- $911.80M
- FCF YoY
- 70.79%
- 52W High
- $89.98
- 52W Low
- $54.11
- 50D MA
- $67.69
- 200D MA
- $67.13
- Beta
- 1.45
- Avg Volume
- 5.66M
Get TickerSpark's AI analysis on DXCM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Brown Michael Jon | sell | 1,700 |
| Jun 15, 26 | FOLETTA MARK G | sell | 3,801 |
| Jun 15, 26 | FOLETTA MARK G | sell | 199 |
| Jun 3, 26 | Coleman Jon | sell | 4,912 |
| Jun 4, 26 | Coleman Jon | sell | 4,911 |
| May 28, 26 | ALTMAN STEVEN R | other | 5,565 |
| May 28, 26 | Malady Kyle | other | 5,575 |
| May 28, 26 | AUGUSTINOS NICHOLAS | other | 5,575 |
| May 28, 26 | FOLETTA MARK G | other | 6,331 |
| May 28, 26 | Heller Bridgette P | other | 5,575 |
Our DXCM coverage
Recent articles, reports, and earnings notes.
DexCom (DXCM): Margin Recovery Powers Growth Story
DexCom is back to a cleaner growth-and-margin profile, with double-digit revenue gains, expanding profitability, and a net cash balance supporting continued investment. The main debate is whether reimbursement expansion and international growth can offset intense CGM competition.
DexCom, Inc. (DXCM) rises on Elliott stake and board changes
DexCom, Inc. (DXCM) rises after Elliott Investment Management disclosed a stake and reached a cooperation agreement with the company. The move came alongside governance changes, strong Q1 revenue growth, and raised margin guidance, giving investors a clearer case for tighter execution and continued momentum.
Want a deeper read on DXCM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.